New Evidence Links Cabergoline to Complex Angiogenesis Responses in Endometriosis | The 4 Pillar Report

New Evidence Links Cabergoline to Complex Angiogenesis Responses in Endometriosis

Recent studies reveal that cabergoline treatment increases VEGFR-2 Y951 phosphorylation, suggesting an acute signaling response, yet it may paradoxically exert an overall anti-angiogenic effect on endometriotic tissue. This dual action underlines a critical need for targeted time-course studies to better understand the transient pro-angiogenic signaling and its implications for endometriosis management. With moderate risk assigned to current models, further analysis is essential to refine treatment strategies that account for these nuanced mechanisms.

Week 19

New Evidence Links Cabergoline to Complex Angiogenesis Responses in Endometriosis

PILLAR DIAGNOSTIC // WEEK 19

Confidence 72%

“The divergence likely reflects a temporal or compensatory mechanism: cabergoline may transiently increase VEGFR-2 Y951 phosphorylation as an acute signalling response, yet still exert a net anti-angiogenic effect in endometriotic tissue. We assign a moderate risk posture—while the core anti-angiogenic model remains plausible, its mechanistic details require refinement to account for transient pro-angiogenic signalling events.”

Proposed action

Initiate targeted time-course studies measuring both VEGFR-2 phosphorylation and functional angiogenesis endpoints (e.g., microvessel sprouting, endothelial proliferation) at multiple intervals post-cabergoline treatment. Incorporate downstream pathway analyses to distinguish compensatory signalling from sustained angiogenic activity.

THE MECHANICS

Spread & delivery

—

THE MACHINE

Evidence & systems

—

Accelerated aging by GrimAge predicts appetite loss specifically in men over 65, and cabergoline treatment improves oocyte quality in endometriosis even as it paradoxically alters angiogenesis signaling.

THE MAP

Policy & population

—

THE MOOD

Trust & behavior

—

Week 19

Confidence: 72%

The divergence likely reflects a temporal or compensatory mechanism: cabergoline may transiently increase VEGFR-2 Y951 phosphorylation as an acute signalling response, yet still exert a net anti-angiogenic effect in endometriotic tissue. We assign a moderate risk posture—while the core anti-angiogenic model remains plausible, its mechanistic details require refinement to account for transient pro-angiogenic signalling events.

Mechanics

Spread & delivery

Operational layer: transmission pathways, care delivery, supply chains, and how burden moves through systems.

—

No sources

Machine

Evidence & systems

Institutional and clinical bedrock: trials, standards, staffing, capacity, and what the evidence supports.

Audit trail active

The Map

Policy & population

Boundary layer: regulators, jurisdiction, access, demographics, and rules that bound what is possible.

—

No sources

Mood

Trust & behavior

Human response: public trust, compliance, fear or fatigue, and how sentiment shapes real-world uptake.

—

No sources

Systemic divergence ledger

1 conflict detected

Machine

Internal

Cabergoline cannot both inhibit angiogenesis and simultaneously increase phosphorylation of VEGFR-2 Y951, a pro-angiogenic activation marker.

Δ 7.00

Supporting Statements

PubMed

Title not available for this citation.

Cabergolinehas been shown to inhibitangiogenesis in endometriosis

“cabergoline, a dopamine agonist, has been shown to inhibit angiogenesis in endometriosis.”

Apr 13, 26

Contradictory Evidence

PubMed

Title not available for this citation.

Phosphorylation of tyrosine residue 951 on VEGFR-2significantly increasedin the cabergoline-treated group

“However, phosphorylation of tyrosine residue 951 on VEGFR-2 significantly increased in the cabergoline-treated group (p = 0.004).”

Apr 13, 26